drugset / Trial / NCT02108548

A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects

NCT02108548

Phase 1 Terminated 89 enrolled Astellas Pharma Europe B.V.
RandomizedFactorialDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7657 in healthy subjects.

Timeline

Start
2014-04
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP7657 Small molecule Oral
Comparator Naproxen Small molecule Oral

Indications

No indication recorded.